Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)

Date

08 Oct 2016

Session

Gynaecological cancers

Presenters

Jasgit Sachdev

Citation

Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435

Authors

J.C. Sachdev1, M. Maitland2, M. Sharma2, V. Moreno3, V. Boni4, S. Kummar5, B. Gibson6, D. Xuan6, T. Joh6, E. Powell6, A. Jackson-Fisher6, M. Damelin6, X. Xin6, A. Tolcher7, E. Calvo4

Author affiliations

  • 1 Oncology, HonorHealth Research Institute, 85258 - Scottsdale/US
  • 2 Section Of Hematology/oncology, The University of Chicago Medical Centre, Chicago/US
  • 3 Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid/ES
  • 4 Start Madrid, Early Clinical Drug Development Unit, START Madrid-CIOCC. Centro Integral Oncologico Clara Campal, 28050 - Madrid/ES
  • 5 Phase I Clinical Research, Division Of Oncology, Stanford University, Palo Alto/US
  • 6 Early Oncology Development & Clinical Research, Pfizer, San Diego/US
  • 7 Clinical Research, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
More

Resources

Background

PF-06647020, an ADC, comprised of a humanized monoclonal anti-PTK7 antibody, an auristatin, and a cleavable valine-citrulline linker, is being investigated in a Phase I clinical trial in patients (pts) with advanced solid tumors including triple negative breast cancer, non-small cell lung cancer, and OVCA. Here we report safety results and clinical activity in heavily pre-treated or platinum resistant OVCA pts in this ongoing study.

Methods

PF-06647020 was administered intravenously to pts with advanced solid tumors once every 3 weeks (Q3W)/cycle in escalating doses from 0.2 - 3.7 mg/kg until progression. In dose expansion, platinum resistant or refractory OVCA pts (unselected for PTK7 expression) received the recommended phase 2 dose (RP2D). Adverse events (AEs) were evaluated by CTCAE v4.03 and best overall response (BOR) was assessed by RECIST v1.1.

Results

As of May 31, 2016, 76 pts have been treated with PF-06647020, 60 of which were treated at 2.8 mg/kg (identified RP2D) Q3W. Most commonly (≥10%) reported drug related AEs for all pts (mainly Grades 1 - 2) were nausea (46%), alopecia (34%), headache (32%), fatigue (30%), neutropenia (26%), vomiting (22%), decreased appetite (17%), myalgia (15%), arthralgia (11%), and diarrhea (11%). Fourteen pts (18%) experienced Grade ≥3 drug related neutropenia and 3 pts (4%) discontinued due to drug related AEs [pruritus (Grade 2) and fatigue (Grades 2 and 3)]. Twenty-nine recurrent OVCA pts with ECOG PS 0-1 (median age 58.5 yrs [42-77]) were treated at RP2D or 2.1 mg/kg (1 pt). Of 22 pts currently evaluable for BOR assessment, 1 pt had CR, 5 pts had PR (4 were platinum resistant) with ORR 27% (95% CI: 13%, 48%), 12 pts (55%) had SD, and 4 pts (18%) had PD. Median duration of treatment is 3 cycles (range 1–13), and 10 pts remain on treatment. Exploratory immunohistochemistry staining by a validated assay on archival tumors showed all OVCA pts had PTK7 expression.

Conclusions

Encouraging clinical responses have been observed in patients with heavily pre-treated or platinum resistant OVCA. PF-06647020 has an acceptable safety profile and is being further developed.

Clinical trial identification

NCT02222922

Legal entity responsible for the study

Pfizer

Funding

Pfizer

Disclosure

J.C. Sachdev: 1. Pfizer Investigator 2. Previous research funding from Pfizer for an IIT. M. Maitland, M. Sharma, V. Moreno, V. Boni, S. Kummar: 1. Pfizer Investigator. B. Gibson, D. Xuan, T. Joh, E. Powell, A. Jackson-Fisher, M. Damelin, X. Xin: 1. Pfizer employee 2. Pfizer stock owner. A. Tolcher: 1. Pfizer Investigator 2. Past advisory board member - all honoraria paid to START. E. Calvo: 1. Pfizer Investigator.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings